From allosteric drugs to allo-network drugs: State of the art and trends of design, synthesis, and computational methods

Current Topics in Medicinal Chemistry

Volumn 13, Issue 1, 2013, Pages 2-4

  Csermely, Peter ^c   Nussinov, Ruth ^a,b   Szilágyi, András ^c,d  

^a SAIC FREDERICK INC   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Allo network drugs; Allosteric drugs; Glutamatergic transmission; Gpcr receptors; Networks; Quaternary structure; Sar landscapes; Schizophrenia

Indexed keywords

AMPA RECEPTOR; G PROTEIN COUPLED RECEPTOR; INTEGRASE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; PHENYLALANINE 4 MONOOXYGENASE; PORPHOBILINOGEN SYNTHASE; PREALBUMIN; PYRUVATE KINASE; TUMOR NECROSIS FACTOR ALPHA;

ALLOSTERISM; BIOLOGY; CHEMICAL STRUCTURE; DESENSITIZATION; DRUG DESIGN; DRUG MECHANISM; DRUG SYNTHESIS; DYNAMICS; EDITORIAL; HUMAN; METABOLIC DISORDER; NONHUMAN; PROTEIN PROTEIN INTERACTION; PROTEIN QUATERNARY STRUCTURE; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; SYNAPTIC TRANSMISSION;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84876740174     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313010002     Document Type: Editorial

References (26)

1. Luttrell, L. M.; Kenakin, T. P. Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. Methods Mol. Biol. 2011, 756, 3-35.
2. Milligan, G.; Smith, N. J. Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol. Sci. 2007, 28, 615-620.
3. Fliri, A. F.; Loging, W. T.; Volkmann, R. A. Cause-effect relationships in medicine: a protein network perspective. Trends Pharmacol. Sci. 2010, 31, 547-555.
4. Jaffe, E. K. Morpheeins -- new structural paradigm for allosteric regulation. Trends Biochem. Sci. 2005, 30, 490-497.
5. Nussinov, R.; Tsai, C. J. The different ways through which specificity works in orthosteric and allosteric drugs. Curr. Pharm. Des. 2012, 18, 1311-1316.
6. Müller, C.E.; Schiedel, A.C.; Baqi, Y. Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development. Pharmacol. Ther. 2012, 135, 292-315.
7. Csermely, P.; Korcsmáros, T.; Kiss, H.J.M.; London, G.; Nussinov, R. Structure and dynamics of biological networks: a novel paradigm of drug discovery. A comprehensive review. Pharmacol. Therap. 2013, in press, preprint: http://arxiv.org/abs/1210.0330.
8. Lefkowitz, R. J.; Kobilka, B. K; Caron, M. G. The new biology of drug receptors. Biochem. Pharmacol. 1989, 38, 2941-2948.
9. Benovic, J. L. G-protein-coupled receptors signal victory. Cell 2012, 151, 1148-1150.
10. Kenakin, T. P. Allosteric drugs and seven transmembrane receptors. Curr. Top. Med. Chem. 2013, 13, in press.
11. Hudson, B.; Ulven, T.; Milligan, G. The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. Curr. Top. Med. Chem. 2013, 13, in press.
12. Bajorath, J.; Peltason, L.; Wawer, M.; Guha, R.; Lajiness, M. S.; Van Drie, J. H. Navigating structure-activity landscapes. Drug Discov. Today 2009, 14, 698-705.
13. Conn, J. P.; Christopoulus, A.; Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Reviews Drug Discovery 2009, 8, 41-54.
14. Zhao, Z.; Wisnoski, D. D.; O'Brien, J. A.; Lemaire, W.; Williams, D. L., Jr.; Jacobson, M. A.; Wittman, M.; Ha, S. N.; Schaffhauser, H.; Sur, C.; Pettibone, D. J.; Duggan, M. E.; Conn, P. J.; Hartman, G. D.; Lindsley, C. W. Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. Bioorg. Med. Chem. Lett. 2007, 17, 1386-1391.
15. Wood, M.R.; Hopkins, C.R.; Brogan, J.T.; Conn, P.J.; Lindsley, C.W. Molecular switches on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry 2011, 50, 2403-2410.
16. Menniti, F. S.; Lindsley, C. W.; Conn, P. J.; Pandit, J.; Zagouras, P.; Volkmann, R. A. Allosteric modulators for the treatment of schizophrenia: Targeting glutamatergic networks. Curr. Top. Med. Chem. 2013, 13, in press.
17. Jaffe, E. K. Impact of quaternary structure dynamics on allosteric drug discovery. Curr. Top. Med. Chem. 2013, 13, in press.
18. Nussinov, R.; Tsai, C. J.; Csermely, P. Allo-network drugs: harnessing allostery in cellular networks. Trends Pharmacol. Sci. 2011, 32, 686-693.
19. Szilágyi, A.; Csermely, P.; Nussinov, R. Allo-network drugs: extension of the allosteric drug concept to protein-protein interaction and signaling networks. Curr. Top. Med. Chem. 2013, 13, in press.
20. Sun, J.; Jia, P.; Fanous, A. H.; van den Oord, E.; Chen, X.; Riley, B. P.; Amdur, R. L.; Kendler, K. S.; Zhao, Z. Schizophrenia gene networks and pathways and their applications for novel candidate gene selection. PLoS ONE 2010, 5, e11351.
21. Sullivan, P. F. Puzzling over schizophrenia: schizophrenia as a pathway disease. Nat. Med. 2012, 18, 210-211.
22. Ayalew, M.; Le-Niculescu, H.; Levey, D. F.; Jain, N.; Changala, B.; Patel, S. D.; Winiger, E.; Breier, A.; Shekhar, A.; Amdur, R.; Koller, D.; Nurnberger, J. I.; Corvin, A.; Geyer, M.; Tsuang, M. T.; Salomon, D.; Schork, N. J.; Fanous, A. H.; O'Donovan, M. C.; Niculescu, A. B. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol. Psychiatry 2012, 17, 887-905.
23. Monod, J.; Wyman, J.; Changeux, J. P. On the nature of allosteric transitions: A plausible model. J. Mol. Biol. 1965, 12, 88-118.
24. Koshland, D. E. Jr.; Némethy, G.; Filmer, D. Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry. 1966, 5, 365-385.
25. Csermely, P.; Palotai, R.; Nussinov R. Induced fit, conformational selection and independent dynamic segments: an extended view of binding events. Trends Biochem. Sci. 2010, 35, 539-546.
26. Frauenfelder, H.; Sligar, S. G.; Wolynes, P. G. The energy landscapes and motions of proteins. Science 1991, 254, 1598-1603.